GNSC Genaissance Pharmaceuticals (MM)

Genaissance Pharmaceuticals, Inc. Invites You to Participate in its First Quarter 2005 Conference Call NEW HAVEN, Conn., April 26 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that the Company would conduct a conference call on Tuesday, May 3, 2005, at 11:00 a.m. Eastern time (ET), in conjunction with the release of its financial results for the first quarter ended March 31, 2005. To participate in this conference call, dial 719-457-2629, confirmation code 4544361, shortly before 11:00 a.m. ET. A replay of the call will be available from 2:00 p.m. ET through midnight Monday, May 9, 2005. The replay number is 719-457-0820, confirmation code 4544361. Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy is designed to enable Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development. For more information on Genaissance, visit the company website at: http://www.genaissance.com/. DATASOURCE: Genaissance Pharmaceuticals, Inc. CONTACT: Rhonda Chiger, +1-917-322-2569, of Rx Communications Group, for Genaissance Pharmaceuticals, Inc. Web site: http://www.genaissance.com/

Copyright